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Background: The benefits from expedited diagnosis of symptomatic cancer are uncertain. We aimed to analyse the relationship
between stage of colorectal cancer (CRC) and the primary and specialist care components of the diagnostic interval.
Methods:We identified seven independent data sets from population-based studies in Scotland, England, Canada, Denmark and
Spain during 1997–2010 with a total of 11 720 newly diagnosed CRC patients, who had initially presented with symptoms to a
primary care physician. Data were extracted from patient records, registries, audits and questionnaires, respectively. Data sets
were required to hold information on dates in the diagnostic interval (defined as the time from the first presentation of symptoms
in primary care until the date of diagnosis), symptoms at first presentation in primary care, route of referral, gender, age and
histologically confirmed stage. We carried out reanalysis of all individual data sets and, using the same method, analysed a pooled
individual patient data set.
Results: The association between intervals and stage was similar in the individual and combined data set. There was a statistically
significant convex (--shaped) association between primary care interval and diagnosis of advanced (i.e., distant or regional) rather
than localised CRC (P¼ 0.004), with odds beginning to increase from the first day on and peaking at 90 days. For specialist care, we
saw an opposite and statistically significant concave (,-shaped) association, with a trough at 60 days, between the interval and
diagnosis of advanced CRC (Po0.001).
Conclusions: This study provides evidence that longer diagnostic intervals are associated with more advanced CRC. Furthermore,
the study cannot define a specific ‘safe’ waiting time as the length of the primary care interval appears to have negative impact
from day one.
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The diagnostic interval for cancer is defined as the time from first
presentation of symptoms in primary care to diagnosis (Weller et al,
2012). There is a general public perception – largely shared by health
professionals – that prolonged diagnostic intervals lead to poorer
cancer outcome (Richards, 2009). Existing epidemiological evidence
on the relationship between diagnostic interval and outcomes in
colorectal cancer (CRC) is contradictory, most of it suggesting no
statistically significant association (Ramos et al, 2007, 2008;
Neal et al, 2015). Many of these studies are undermined by
negative bias due to confounding by indication and lead-time, but
the lack of clear evidence has nonetheless led some to question the
current use of healthcare and research resources to reduce cancer
delays (Rupassara et al, 2006; Murchie et al, 2014).
Most CRC patients present initially to a primary care physician
(PCP) and are subsequently referred to specialist cancer centres for
assessment and investigation (Hamilton and Sharp, 2004;
Hamilton, 2010; Hansen et al, 2011; Banks et al, 2014). National
guidelines such as the English NICE Guidance, the Scottish SIGN
Guidelines and the Danish Cancer Patient Pathways, recommend
urgent referral of patients with alarm signs and symptoms,
including unexplained weight loss, change in bowel habit and/or
rectal bleeding (NICE, 2005; SIGN, 2003; Probst et al, 2012).
However, over half of people subsequently diagnosed with
colorectal cancer have no alarm signs or symptoms at initial
presentation to a PCP (Hamilton et al, 2005). These patients may
experience longer diagnostic intervals, perhaps as a result of not
being referred until alarm symptoms develop, or because
they are ineligible for an urgent appointment (Neal et al, 2014;
Jensen et al, 2014a).
We propose a temporal and relational way of understanding the
association between time to diagnosis and CRC outcomes. In short,
the temporal idea is that cancers become gradually easier to detect
with time due to the exponential growth of tumours. The relational
idea is that doctors exert their ability to identify cancer by virtue of
the role they perform within the relational network to which they
belong. It is our hypothesis that symptomatic cancer patients are
being sorted and diagnosed at different pace based on their
gradually changing clinical indications, and on the respective
diagnostic tools available in primary and specialist care. This must
be taken into account when analysing the prognostic influence of
delays.
We identified seven CRC cohort studies to create a data set
sufficiently large to investigate the association between time to
diagnosis and CRC outcomes. To call attention to the inevitable
problem of confounding by indication and explain continued lack
of evidence, we analysed stage of CRC as a flexible function of the
length of time under PCP care and specialist care, respectively.
MATERIALS AND METHODS
We identified seven studies with data sets from Scotland, England,
Canada, Denmark and Spain from population-based studies of
incident CRC patients diagnosed between 1997 and 2010. Data sets
were required to hold information on dates in the diagnostic
interval (Weller et al, 2012), symptoms at first presentation in
primary care, route of referral, gender, age and stage. All but one
(ALBERTA) have published their results (Robertson et al, 2004;
Hamilton et al, 2005; Stapley et al, 2006; Korsgaard et al, 2006a, b;
Esteva et al, 2007, 2013; Rubin et al, 2011; Lyratzopoulos et al,
2013; Murchie et al, 2014; Jensen et al, 2014b). The individual
studies are summarised in Table 1 and more extensively described
in the Supplementary Material I.
Study population. All cohorts described in this study were from
jurisdictions with publicly funded, universal health-care systems, in
which PCPs act as gatekeepers from primary to specialist care.
Newly diagnosed CRC patients were identified in discharge
registries, hospital or primary care records. From each data set,
we included all patients aged 20 years and over who had attended
primary care before the cancer diagnosis. Screen-detected cases
were excluded, as were those diagnosed as a result of emergency
presentation with no prior contact with primary care. To render
the data sets uniform, we only included patients with recorded
CRC symptoms or CRC-related visits in the year before diagnosis
(Stapley et al, 2006).
Defining exposures, outcome and covariates. We defined and
calculated three exposure variables as illustrated on Figure 1:
(1) The primary care interval (time from first presentation to referral
to a cancer specialist centre); (2) the secondary care interval (time
from referral to diagnosis); and (3) the total diagnostic interval (time
from first presentation to diagnosis) based on information on date of
first presentation of symptoms in primary care and date of referral
to a cancer specialist centre, and date of diagnosis, as defined in the
Aarhus Statement (Weller et al, 2012). All data sets, except the
NACDPC, recorded the date of diagnosis, defined as date of first
histological confirmation of the malignancy in accordance with the
hierarchy produced by the European Network of Cancer Registries
(Supplementary Material I).
The primary outcome of the study was stage of CRC as defined
by the local registry or provincial cancer registry in the case of the
ALBERTA cohort (Table 1). All data sets included histologically
confirmed stage, except the NACDPC data set, which used a
simplified staging equating to SEER stages 0–3 that was
determined by the PCP using information contained in cancer
specialist letters. We used T, N and M and not Dukes’ stage where
both were available. Stage data were re-categorised to localised,
regional, distant, or unknown; and then further simplified to a
binary variable of advanced (i.e., distant or regional) vs localised
CRC (Supplementary Table 1 shows the algorithm for colorectal
cancer staging according to classification system).
All data sets included data on gender, age at diagnosis and
presenting symptoms. ‘Alarm symptoms at first presentation’ (yes/
no), were defined based on whether patients’ reported symptom(s)
merited urgent referral according to the UK’s NICE guidelines
(NICE, 2005; Neal et al, 2014) (Supplementary Table 2 shows the
pre-specified lists of colorectal cancer symptoms recorded in each
data set).
Statistical analyses. Each data set was analysed separately, then
combined for pooled individual patient data analysis. Time
intervals are presented as medians with interquartile intervals
(IQI). To test for confounding factors related to clinical triage, we
estimated the difference in median care intervals between patients
with and without ‘alarm symptoms’ and ‘emergency admission’ or
not using quantile regression analysis (Supplementary Table 3;
Supplementary Figures 4 and 5).
To avoid assuming a linear or piecewise constant association
between care intervals and stage, we treated primary and secondary
care intervals as continuous variables, using restricted cubic splines
with three knots and 30 days as the reference point (Durrleman
and Simon, 1989). We estimated the odds ratio of being diagnosed
with advanced vs localised CRC as a function of the length of each
care interval using logistic regression. We adjusted for age (20–64/
65–74/X75 years), gender and alarm symptoms. With the
combined data, we allowed for between-data set variability by
adjusting for cohort. We combined interval data with no attention
to distributions or weights. Eight sensitivity analyses tested the
robustness of the model (Supplementary Table 5).
We tested each model against a model with no care interval
term using the Wald test. A two-sided P-value of 0.05 or less was
defined as significant. Analyses were done using Stata v. 14
(StataCorp LP, College Station, TX, USA).
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Table 1. Study characteristics of seven colorectal cancer cohort data sets
Cohort
name
CRUX CAPER CRCDK ALBERTA CAP DECCIRE NACDPC
Project Comparing rural and urban
cancer care
Cancer prediction in
Exeter
Colorectal cancer in
Denmark
Not named Cancer in primary care Delay cancer colon i recto National audit of cancer
diagnosis in primary care
Reference Robertson et al, 2004;
Murchie et al, 2014
Hamilton et al, 2005;
Stapley et al, 2006
Korsgaard et al, 2006a,
2006b; Iversen et al, 2009
Unpublished Jensen et al, 2014a,
2014b
Esteva et al, 2007, 2013 Rubin et al, 2011;
Lyratzopoulos et al, 2013
Population Scotland England Denmark Canada Denmark Spain England
Region/county Highland and Grampian
regions
Devon county Aarhus, Ringkoebing and
Ribe counties
Province of Alberta Aarhus County (CAP1)
Central and Southern DK
(CAP2)
All of Denmark (CAP3)
Baleares, Galicia,
Valencia, Catalunya and
Arago´n regions
1170 volunteering practices
from 20 Cancer Networks
representing 14% of all
practices in England
Study period Jan 1997–Dec 1998 Jan 1998–Dec 2002 Jan 2001–July 2002 Jan 2004–Dec 2008 Sept 2004–Aug 2005
(CAP1)
Oct 2007–Sept 2008
(CAP2)
May 2010–Aug 2010
(CAP3)
Sept 2006–Sept 2008 April 2009–April 2010
Study design Registry-based Registry-based Patient-based Registry-based PCP-based Patient-based PCP-based
Identification Scottish Cancer Registry Exeter Cancer Registry Hospital departments Provincial Cancer Registry Hospital Discharge
Registry
Hospital departments English Cancer Networks
Disease
classification
ICD-10 C18, C19 and C20 ICD-O-3 8140, 8480, 8490,
8020
ICD-10 C18, C19 and C20 ICD-10 C18, C19 and C20 ICD-10 C18, C19 and C20 ICD-9 153–154 ICD-10 C18, C19 and C20
Validation Histological confirmation Histological confirmation Histological confirmation
(Pathology reports)
Histological confirmation Histological confirmation
(Danish Cancer Registry)
Histological confirmation
(pathology reports)
Practice records including
hospital correspondence
Data sources Primary care records and
governmental hospital
admissions data
Electronic primary care
record
Interviewer-administered
patient questionnaires
Physician billings and
hospital records
PCP-questionnaires
requesting dates from
electronic patient files
and hospital discharge
letters
Patient interviews
combined with review of
primary care and hospital
records
PCP-audit tool requesting
dates from practice records
and hospital correspondence
Definitions Algorithm Case-Control review Interview Algorithm Questionnaire Interview and review Audit
Date of
presentation
Earliest recorded
colorectal cancer symptom
in the year before
diagnosis
Earliest recorded
colorectal cancer symptom
in the year before date of
diagnosis
‘When did you first present
the above stated
symptoms to a doctor?’
The earlier of: first
recorded CRC symptom
or PCP visit prior to first
CRC procedure in the year
before diagnosis
‘When did the patient first
present to your practice
with symptoms which you
think are related to the
current cancer diagnosis?’
Researchers browsed
primary care records
First notification to any
health-care professional
working within the Primary
Health-Care Team about a
probable symptom or sign of
cancer
Date of referral Date of first PCP referral or
date of emergency
admission to hospital
Not collected ‘When were you referred
to hospital for further
investigation?’
Date of first PCP visit prior
to colonoscopy or other
CRC-related procedure
‘At which date did you/
your practice decide to
refer the patient for
further investigation?’
Researchers browsed
primary care records, but
not in the Arago´n region
(n¼ 214)
Referral to secondary care for
further investigation or
management of probable
symptom or sign of cancer
Date of diagnosis Scottish Cancer Registry
incidence date
Date of positive histology
or date given by the
specialist
‘What decisive
examination led to your
current hospitalisation?’
Date in cancer registry
which is almost always the
date of first positive
histology
Danish Cancer Registry
incidence date
Date of positive histology
(date of the first
pathology report)
Not collected
Tumour stage Dukes Dukes Dukes and TNM TNM TNM TNM SEER 2–4
Symptom data 17 CRC symptoms (ICPC) 11 CRC symptoms (ICPC) 17 CRC symptoms
(patients’ first symptom
experience)
12 CRC symptoms 11–22 cancer symptoms
presented in primary care
9 CRC symptoms
(patients’ first symptom
experience)
11 CRC symptoms (ICPC)
Emergency
admission
Type of first hospital
visit¼A&E and emergency
admission according to
hospital admission data
Surgical admission for
suspected bowel
obstruction or perforation
with CRC diagnosed
during admission
‘How were you admitted to
the surgical department’
response: acute or sub-
acute admission
Emergency admission with
CRC-related issue within 7
days prior to diagnosis
Acute or sub-acute
admission according to
National Patient Registry
NB: Not collected for the
second and third
subcohort (n¼ 1569)
Route to
diagnosis¼ emergency
department according to
hospital record
Type of referral¼ emergency
according to primary care
record (audit tool)
Abbreviations: CRC¼ colorectal cancer; ICD-10¼ International Classification of Diseases 10th revision; ICD-9 International Classification of Diseases 9th revision; ICD-O-3¼WHO International
Classification of Disease for Oncology; ICPC¼ International Classification of Primary Care; PCP¼primary care physician; SEER¼ Surveillance, Epidemiology and End Results (cancer reporting
standard of the National Cancer Institute); TNM¼Tumour, node, metastasis. Study characteristics of seven colorectal cancer cohort data set.
Diagnostic interval
Symptoms Date of diagnosis/
histology
A B D
Date of referral
C
Date of first presentation
in primary care
Primary care
interval
Secondary care
interval
Figure 1. Definition of exposure variables.We calculated three exposure variables based on information on date of first presentation of symptoms
in primary care (B); date of referral to a cancer specialist centre (C); and date of diagnosis (D). ‘The primary care interval’ is defined as (B, C)¼ time
from first presentation to referral to a cancer specialist centre. ‘The secondary care interval’ is defined as (C, D)¼ time from referral to diagnosis).
‘The total diagnostic interval’ is defined as (B, D)¼ time from first presentation to diagnosis. Information on date of first symptom (A) was not
available.
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RESULTS
In total, the seven data sets included 15 023 incident CRC patients.
Of these, 1584 (11%) did not consult a PCP before their diagnosis
of CRC, and 1719 had incomplete data; these were excluded. Of the
remaining 11 720 patients, 11 187 (95%) had information on
primary care interval; 9163 (78%) on secondary care interval and
9696 (83%) on the total diagnostic interval. Stage information was
available for 92% (Table 1 and Figure 2).
The median age for all patients combined was 70 years; 56% were
males, 59% presented with alarm symptoms, 20% were emergency
hospital admissions, 61% had colon and 39% rectal cancer; 44% had
localised CRC. Clinical features were remarkably similar for each of
the seven cohorts, except for the proportion of patients presenting
with alarm symptoms, which varied from 49% (DECIRRE) to 78%
(CAPER); and the proportion of emergency admissions, which varied
from 10% (CRCDK) to 43% (DECCIRE) (Table 2).
Total diagnostic interval and its primary care and secondary
care components. The overall median primary care interval was 5
days (interquartile interval (IQI): 0–39), ranging from 2 days (IQI:
0–21) in CAP to 14 days (IQI: 0–64) in CRUX. Thirty nine per
cent of patients were referred immediately after presentation (i.e.,
primary care interval of zero days) varying from 14% in CRUX to
46% in the CAP and ALBERTA cohorts (Supplementary Figure 1).
The overall median secondary care interval was 20 days (IQI: 7–46)
and varied from 14 days (IQI: 7–29) in CRCDK to 38 days (IQI:
17–82) in DECCIRE (Table 2; Supplementary Figure 2). The
overall median diagnostic interval was 46 days (IQI: 18–105)
ranging from 35 days in CAP to 97 days in CAPER (Table 2;
Supplementary Figure 3).
The adjusted care intervals were significantly shorter for
patients with alarm symptoms and for patients with emergency
admissions. Overall, patients waited an additional 6 (95%
confidence interval (CI): 4–7) days from presentation to referral
and an additional 9 (95% CI: 7–10) days from referral to diagnosis
at the 50th percentile if they had no alarm symptoms. An
emergency admission shortened the secondary care interval by 18
(95% CI: 17–19) days at the 50th percentile. Alarm symptoms
consistently shortened the length of the primary care interval in
each cohort, whereas emergency admissions more convincingly
affected the length of the secondary care interval (Supplementary
Table 3; Supplementary Figures 4 and 5).
Primary and secondary care diagnostic intervals and stage of
CRC. For the combined cohort, we observed a significant trend for a
concave, --shaped association with increasing and subsequently
decreasing odds of advanced CRC with longer primary care intervals
(P¼ 0.004). The point-wise estimates showed that the adjusted odds of
being diagnosed with an advanced stage tumour increased from the
first day, and were around 8% (95% CI: 2–12%) higher for patients
who waited 90 days compared to 30 days from first presentation to
referral (Figure 3, blue curve). For the secondary care interval, we saw
the reverse effect: a significant ,-shaped association with decreasing
and subsequently increasing odds of advanced CRC with longer
secondary care intervals (Po0.001) (Figure 3, red curve). Crude
estimates were similar to the adjusted curves on Figure 3 (not shown).
The cohort-specific associations were consistent with the overall
trend (Figures 4 and 5), but the primary care interval model was
only significant for CRUX (P¼ 0.03); and the secondary care
interval model was only significant for ALBERTA (Po0.001) and
CAP (Po0.001) data. For the total diagnostic interval, we found
decreasing odds of advanced CRC with longer intervals
(Po0.001), but not achieving significance in individual cohorts
(Supplementary Figure 6).
The findings were similar after including patients with unknown
tumour stage (915 patients) or restricting the analysis to patients
with/without alarm symptoms or with/without emergency admission.
Excluding the 41% of patients with zero days of primary care interval
(zero-inflation) decreased the primary care interval trend. These
sensitivity analyses are shown in Supplementary Table 5.
DISCUSSION
In this unique pooled individual patient data analysis of seven
cohorts with 11 720 incident CRC patients attending primary care
with symptoms before diagnosis, the odds of advanced CRC
increased with longer primary care intervals up to B90 days, after
Eligible:
Incident CRC patients ≥ 20 years
Eligible with no data, n (% of eligible):
Eligible patients with no or incomplete data
0 (0) 0 (0) 211 (22) 0 (0) 1071 (35) 26 (3) 411 (16) 1719 (11)
Excluded, n (%of eligible):
Eligible patients who did not present in primary care: 355 (31) 30 (9) 127 (13) 532 (9) 155 (5) 254 (34) 131 (5) 1584 (11)
1) No recorded symptoms one year
before diagnosis 1042 (7)35 (5)69 (2)532 (9)51 (5)30 (9)325 (28)
2) No GP involvement 542 (4)131 (5)219 (29)86 (3)76 (8)30 (3)
Included study subjects, n (% of eligible): 802 (69) 319 (91) 613 (64) 5657 (91) 1841 (60) 464 (62) 2024 (79) 11720 (78)
Study subjects with recorded:
Primary care interval, n (% of combined)
Secondary care interval , n (% of combined)
Total diagnostic interval, n (% of combined)
802 (7)
802 (9)
802 (8)
0 (0)
0 (0)
319 (3)
613 (5)
613 (7)
613 (6)
5657 (51)
5657 (62)
5657 (58)
1841 (16)
1841 (20)
1841 (19)
250 (2)
250 (3)
464 (5)
2024 (18)
0 (0)
0 (0)
11187 (95)
9163 (78)
9696 (83)
Stage info:
10333 (92)
8415 (92)
8907 (92)
NACDPC CombinedCRUX CAPER CRCDK ALBERTA CAP DECCIRE
1157 349 951 6189 3067 744 2566 15023
Primary care interval
Secondary care interval
Total diagnostic interval
Figure 2. Patient flow for each colorectal cancer cohort data set and all data combined. CAP¼Cancer in Primary Care; CAPER¼Cancer Prediction
in Exeter; CRC¼ colorectal cancer; CRCDK¼Colorectal Cancer in Denmark; CRUX¼Comparing Rural and Urban Cancer Care; DECCIRE¼Delay
Cancer Colon i Recto; NACDPD¼National Audit of Cancer Diagnosis in Primary Care.
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1.8Odds
ratio
0 1 14
Blue: Primary care interval, combined N= 10 333
Red: Secondary care interval, combined N= 8415
30 60 90
DAYS
120 180 240 300 365
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
0.9
0.8
0.7
~ 0.85 (95% CI: 0.80–0.88)
~ 1.08 (95% CI: 1.02–1.12)
Figure 3. The risk of being diagnosed with advanced colorectal cancer as a function of time to diagnosis. Estimated odds ratios of being
diagnosed with advanced (distant or regional) vs localised colorectal cancer as a function of the length of the primary care interval (blue) and the
secondary care interval (red) analysed for all cohorts combined (patients with unknown tumour stage excluded). We adjusted for age, gender,
alarm symptoms and cohort. The area around the fitted curves indicates 95% confidence limits. The spikes below the curves show the distribution
of the primary care interval (blue) and secondary care interval (red) on a squared scale. The grey horizontal lines indicate the chosen reference
point of 30 days (see logistic regression details in Supplementary Table’4, Supplementary Material IV). Crude estimates are not shown.
Table 2. Clinical features for patients attending general practice before diagnosis displayed for each colorectal cancer cohort
data set and all data combined
CRUX CAPER CRCDK ALBERTA CAP DECCIRE NACDPC COMBINED
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Study subjects 802 (7) 319 (3) 613 (5) 5657 (48) 1841 (16) 464 (4) 2024 (17) 11 720 (100)
Time intervals, median (IQI) days
Primary care interval 12 (2–64) NA 6 (0–45) 3 (0–48) 1 (0–21) 14 (0–50)a 6 (0–32) 5 (0–39)
Secondary care interval 21 (3–47) NA 14 (7–29) 18 (6–46) 23 (9–45) 38 (17–82)a NA 20 (7–46)
Diagnostic interval 55 (21–148) 97 (44–218) 31 (13–84) 47 (18–109) 35 (16–73) 67 (28–132) NA 46 (18–105)
Alarm symptoms of cancer
No 306 (38) 70 (22) 236 (38) 2708 (48) 617 (34) 237 (51) 631 (31) 4805 (41)
Yes 496 (62) 249 (78) 377 (62) 2949 (52) 1224 (66) 227 (49) 1393 (69) 6915 (59)
Emergency admission
No 592 (74) 264 (83) 551 (90) 4486 (79) 204 (75)b 263 (57) 1739 (86) 8099 (80)
Yes 210 (26) 55 (17) 62 (10) 1171 (21) 68 (25)b 201 (43) 285 (14) 2052 (20)
Tumour site
Colon 498 (62) 196 (61) 368 (60) NA 1147 (62) 264 (57) NA 2473 (61)
Rectum 304 (38) 123 (39) 245 (40) NA 694 (38) 200 (43) NA 1566 (39)
Sex
Females 350 (44) 154 (48) 280 (46) 2378 (42) 883 (48) 177 (38) 940 (46) 5162 (44)
Males 452 (56) 165 (52) 333 (54) 3279 (58) 958 (52) 287 (62) 1084 (54) 6558 (56)
Age at diagnosis
20–64 years 206 (26) 80 (25) 217 (35) 2184 (39) 599 (33) 142 (31) 614 (30) 4042 (34)
65–74 years 276 (34) 96 (30) 200 (33) 1567 (28) 583 (32) 145 (31) 582 (29) 3449 (29)
X75 years 320 (40) 143 (45) 196 (32) 1906 (34) 659 (36) 177 (38) 828 (41) 4229 (36)
Median age (IQI) 72 (64–79) 73 (65–80) 70 (62–77) 69 (59–77) 71 (62–79) 72 (62–78) NA 70 (60–78)
Stage
Localised 341 (43) 167 (52) 299 (49) 2709 (48) 586 (32) 213 (46) 823 (41) 5138 (44)
Regional 251 (31) 91 (29) 186 (30) 1536 (27) 488 (27) 128 (28) 647 (32) 3327 (28)
Distant 99 (12) 37 (12) 114 (19) 1140 (20) 438 (24) 84 (18) 448 (22) 2360 (20)
Unknown 111 (14) 24 (8) 14 (2) 272 (5) 329 (18) 39 (8) 106 (5) 895 (8)
Abbreviation: NA¼ not available.
aIn the DECCIRE data set, the primary and secondary care intervals were only recorded in the Baleares, Galicia, Valencia and Catalunya regions (n¼ 250).
bEmergency admission was only recorded in the 1st subcohort of the CAP data set (n¼ 272).
Clinical features for patients attending general practice before diagnosis displayed for each colorectal cancer cohort data set and all data combined.
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which the odds decreased. Conversely, the odds of advanced CRC
decreased with longer secondary care intervals up to B60 days,
after which the odds slowly increased. Both of these associations
were statistically significant and the trends were consistent across
data sets. No clear trend was noted across individual cohorts for
the total diagnostic intervals.
Strengths and limitations. The key strength of this study lies in
the large number of cases, from seven data sets in five countries
with comparable systems of universal health-care. By excluding
screen-detected patients and those without PCP involvement, the
results are relevant to all health-care systems featuring primary
care gate-keeping. However, the proportions of patients presenting
2.0Odds
ratio 1.8
1.6
1.4
1.2
1.1
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0 1 14
CRUX ALBERTA
DECCIRE
NACDPC
CRCDK
CAP
30 60 90
Primary care interval (days)
120 180 240 300 365
Figure 4. The risk of being diagnosed with advanced colorectal cancer as a function of time from presentation to referral. Estimated odds ratios
of being diagnosed with advanced (distant or regional) vs localised colorectal cancer as a function of the length of the primary care interval (time
from first presentation of symptoms to referral); analysed for six cohorts (in total 10 333 patients). We excluded patients with unknown tumour
stage excluded and adjusted for age, gender and alarm symptoms at first presentation. The grey dashed curves with 95% confidence limits are
fitted on the combined data sets with grey spikes showing the distribution of the care intervals on a squared scale. The grey horizontal lines
indicate the chosen reference point of 30 days. Crude estimates are not shown.
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Figure 5. The risk of being diagnosed with advanced colorectal cancer as a function of time from referral to diagnosis. Estimated odds ratios of
being diagnosed with advanced (distant or regional) vs localised colorectal cancer as a function of the length of the secondary care interval (time
from referral to diagnosis) analysed for five cohorts (in total 8415 patients). We excluded patients with unknown tumour stage and adjusted for age,
gender and alarm symptoms at first presentation. The grey dashed curves with 95% confidence limits are fitted on the combined data sets with
grey spikes showing the distribution of the care intervals on a squared scale. The grey horizontal lines indicate the chosen reference point of 30
days. Crude estimates are not shown.
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as an emergency are not routinely recorded outside the UK, so we
cannot know whether varying sizes of this proportion have affected
our results. The data were sufficiently detailed to enable care
intervals to be analysed as a continuous variable, enabling us to
utilise recent methodological advances in a larger sample (Tørring
et al, 2011, 2012). A fundamental strength of the study is that lead-
time bias cannot explain results, as we used stage as our outcome
measure, rather than survival time.
A number of limitations exist due to the cross-sectional study
design, which does not permit direct inference of causality. Dates
for interval calculations may have been recorded systematically
differently across different data sets. Although the ascertainment of
dates accorded with best practice in all cases (Weller et al, 2012),
no gold standard data source exists for interval measures. Studies
show good agreement between patient and PCP recorded dates of
diagnosis (Adelstein et al, 2008); but dates of first presentation are
usually more accurately recorded for alarm symptoms than
for non-specific symptoms (Lynch et al, 2008). Furthermore,
registry-based interval measures may be affected by the data
collection methods, with some symptoms unrecorded, whereas
others are potentially unrelated to the cancer (Stapley et al, 2006;
Tate et al, 2009). Registry-based studies are highly dependent on
underlying algorithms and cut-points; they benefit from high
inclusion rates, but potentially have non-differential misclassifica-
tion of date of first presentation. To ensure that registry-based
recorded symptoms were likely to be related to the cancer, we only
included recorded CRC symptoms or CRC-related visits in the
year before diagnosis. Even so, registry-based measures were
longer than PCP-reported time points (Table 2; Supplementary
Figures 1–3).
Missing information bedevils all studies on staging, and may
have biased results if the quality of staging was associated with
diagnostic timeliness. Although we used benchmarked registries
and approaches to produce comparable stage information (Tucker
et al, 1999; Ostenfeld et al, 2012; Walters et al, 2013;
Benitez-Majano et al, 2016), it is conceivable that there was some
bias to exclusion of more advanced cases in some data sets,
reflecting those dying during admission or treatment. The main
effect of such information bias would be increased variation and
fewer cases with short intervals and advanced stages, and thus
towards no association between time and stage. Hence, our
estimates are perhaps underestimates of the real association.
Despite differences in data sources and construction, the clinical
features of patients were remarkably similar for each of the seven
individual data sets, and they produced strikingly similar results
suggesting that selection and information biases were not major
methodological limitations.
Unmeasured confounding by factors such as socioeconomic
status, co-morbidity, or tumour grade/aggressiveness, which were
not universally available, may have influenced the results. We
partly mitigated this by adjusting for alarm symptoms and
emergency admissions, reducing confounding by indication.
Given the observed trends, it is difficult to predict the direction
of bias. However, most of the potential biases from selection,
information, confounding, and confounding by indication inher-
ited from the different study designs are likely to have caused
negative bias towards and even beyond the null-hypothesis (i.e.,
odds ratio¼ 1).
When interpreting the results from the combined data sets,
the weight of information contributed by each study is relevant.
In a sensitivity analysis excluding ALBERTA (50–61% of
subjects) we found almost identical results (Supplementary
Table 5).
Comparison with findings from other studies. The study builds
on a recent systematic review of the association between time to
diagnosis and cancer outcome for all types of cancers, which called
for higher quality and larger studies that addressed basic issues of
bias (Neal et al, 2015). Few studies have considered the possibility
that the associations may vary for different components of the
diagnostic pathway (Afzelius et al, 1994; Crawford et al, 2002). They
support our interpretation that the basis for assignment of delay (the
sorting of patients) change during the diagnostic pathway and that
interval-specific models are necessary to achieve valid comparisons of
delay and mortality. Our findings also confirm a non-monotonic
relationship between delay and stage, and thus consolidate important
points made by Maguire and others, but in a much larger
cohort enabling more valid models (Maguire et al, 1994;
Tørring et al, 2011, 2012; Murchie et al, 2014).
Underlying mechanisms. It is a widely held assumption that the
waiting time paradox can be explained by the effect of high-risk
precursors such as phenotype, biological virulence or tumour
aggressiveness, which are thought to act as unmeasured con-
founders that mask the effect of the exposure (Afzelius et al, 1994;
Crawford et al, 2002; Symonds, 2002; Neal et al, 2015). However,
some studies have shown that a significant proportion of cancers
present with symptoms that are vague or non-specific, with the
underlying problem more difficult to detect and act upon in time
(Korsgaard et al, 2006b; Jensen et al, 2014a). It is reasonable to
assume that symptomatic cancer patients are sorted and diagnosed
at different pace based on their gradually changing clinical
indications, and on the respective diagnostic tools available in
primary and specialist care.
We believe the finding of a two-sided ‘waiting time paradox’
(lower odds of advanced CRC for very long primary care intervals
and higher odds of advanced CRC for very short secondary care
intervals) reflects confounding by indication, a bias stemming from
the inherent difference in the prognosis of patients given different
medical priority in primary care vs specialist care.
In primary care, PCPs will expedite patients using a fast-track
cancer patient pathway or emergency admission if the patient’s ill-
health is obvious. At the same time, PCPs may be more reluctant to
refer those with low-risk symptoms, leading to use of normal
waiting list referral or watchful-waiting. As many patients in
primary care do not fall squarely into either of these categories,
delays should be less contingent upon prognosis and thus more
randomly distributed in the large group of intermediate patients.
We, therefore, propose that the observed increasing odds of
advanced CRC with longer primary care intervals up toB90 days
reflects the actual effect of primary care delays.
In contrast, when a patient is first seen in specialist care,
primary care triage has already taken place—making the
probability of CRC higher. Furthermore, the specialist’s greater
clinical experience of patients with CRC and ready access to
hospital-based investigations ensures that patients with advanced
disease attending specialist care are diagnosed and treated very
quickly; those with less advanced disease are managed less
urgently. Hence, negative bias (where the observed effect is lower
than the true value) probably explains the decreasing odds of
advanced CRC with time and may explain why many CRC studies
to date have failed to reject the null-hypothesis of no association
between delays and outcome (Ramos et al, 2007, 2008; Neal et al,
2015). As with previous studies, we found no clear association
between the total diagnostic interval and stage, presumably due to
the conflicting selection-effects of primary care and secondary care
intervals. As a final, tentative point, we propose that the
observation of increasing odds of advanced CRC with secondary
care intervals longer thanB60 days could reflect the effect of false
negative tests or unnecessary delays in investigation and/or
treatment.
Clinical implications. We cannot define a specific ‘safe’ waiting
time as the length of the primary care interval appears to have a
BRITISH JOURNAL OF CANCER Advanced stage colorectal cancer with longer diagnostic intervals
894 www.bjcancer.com |DOI:10.1038/bjc.2017.236
negative impact from day one. It follows that patients with CRC,
without alarm symptoms at presentation, are most at risk of a
prolonged diagnostic interval.
Cancer diagnostic delays cannot be completely eradicated, so
resources must be used proportionately to the objective of finding
cancer sooner. Reducing the primary care interval by lowering the
threshold for urgent referral and enabling easier direct access to
investigations by PCPs, may provide the greatest benefit, as other
recent studies indicate (Maclean et al, 2015; Moller et al, 2015).
The study displays the immense complexity and difficulty of
diagnosing cancer. Further research on similar combined data sets
from longitudinal studies, using the same novel analytical
approach, should now be conducted to confirm the relative impact
of primary and secondary care diagnostic intervals on outcomes in
patients with other cancers.
CONCLUSION
This study provides evidence that longer primary care and
secondary care intervals are associated with more advanced CRC.
The finding of similar trends when using different sources of
information, for different time periods and in different health-care
systems (of Scotland, England, Canada, Denmark and Spain)
strengthens the belief that the results can be generalised to other
health-care systems around the world.
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